title: Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma.
authors.forename: Antonio
authors.initials: A
authors.lastname: Grieco
authors.forename: Antonella
authors.initials: A
authors.lastname: Lombardo
authors.forename: Marco
authors.initials: M
authors.lastname: Biolato
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D017984:Enoxaparin / Q000627:therapeutic use; D006331:Heart Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000009:adverse effects*; D011237:Predictive Value of Tests; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D012307:Risk Factors; D000077157:Sorafenib; D013927:Thrombosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D016896:Treatment Outcome; D014463:Ultrasonography; D018754:Ventricular Dysfunction / Q000150:complications
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D017984:Enoxaparin; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib